Literature DB >> 2085670

Modularity of osteoclast behaviour and "mode-specific" inhibition of osteoclast function.

M Zaidi1.   

Abstract

This study is part of an attempt to understand the role of specific cellular activities in the bone resorptive process. Experiments were performed whereby known pharmacological agents were used to inhibit individual modes of osteoclastic activity, such as motility and secretion. The effects of such treatments on bone resorption were assessed by quantitative scanning electron microscopy. The compounds included colchicine, which was used to inhibit osteoclast motility; molybdate ions which were used to selectively inhibit the catalytic activity of secreted acid phosphatase, and omeprazole which was employed to inhibit the secretion of hydrogen ions. All compounds inhibited osteoclastic bone resorption, but singularly affected defined modes of activity. These findings suggest that each mode of osteoclastic activity is essential for the bone resorptive process, and that "mode-specific" inhibition may provide a means whereby excessive activity of the osteoclast can be regulated in disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2085670     DOI: 10.1007/BF01116615

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  13 in total

1.  Substrate influences rat osteoclast morphology and expression of potassium conductances.

Authors:  S A Arkett; S J Dixon; S M Sims
Journal:  J Physiol       Date:  1992-12       Impact factor: 5.182

2.  A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function.

Authors:  M Zaidi; A S Alam; V S Shankar; B E Bax; B S Moonga; P J Bevis; M Pazianas; C L Huang
Journal:  Eur Biophys J       Date:  1992       Impact factor: 1.733

3.  Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

Authors:  Chun-Sick Eom; Sang Min Park; Seung-Kwon Myung; Jae Moon Yun; Jeong-Soo Ahn
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

Review 4.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

Review 5.  Risk of fracture and pneumonia from acid suppressive drugs.

Authors:  Chun-Sick Eom; Sang-Soo Lee
Journal:  World J Methodol       Date:  2011-09-26

6.  Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP.

Authors:  I MacIntyre; M Zaidi; A S Alam; H K Datta; B S Moonga; P S Lidbury; M Hecker; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

7.  Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.

Authors:  Jessica A Cottrell; Francis M Vales; Deborah Schachter; Scott Wadsworth; Rama Gundlapalli; Rasesh Kapadia; J Patrick O'Connor
Journal:  J Biomed Biotechnol       Date:  2010-06-16

8.  Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.

Authors:  F de Vries; A L Cooper; S M Cockle; T-P van Staa; C Cooper
Journal:  Osteoporos Int       Date:  2009-03-31       Impact factor: 4.507

9.  Do proton pump inhibitors decrease calcium absorption?

Authors:  Karen E Hansen; Andrea N Jones; Mary J Lindstrom; Lisa A Davis; Toni E Ziegler; Kristina L Penniston; Amy L Alvig; Martin M Shafer
Journal:  J Bone Miner Res       Date:  2010-06-24       Impact factor: 6.741

10.  Pantoprazole decreases cell viability and function of human osteoclasts in vitro.

Authors:  Markus Prause; Claudine Seeliger; Marina Unger; Elizabeth Rosado Balmayor; Martijn van Griensven; Alexander Tobias Haug
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.